Review article: The biology, diagnosis and management of gastrointestinal stromal tumours

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 12, 2014, Pages 1376-1386

  Iorio, N ^a   Sawaya, R A ^a   Friedenberg, F K ^a  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CELL PROTEIN; DOG1 PROTEIN; IMATINIB; REGORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AGE; ANEMIA; ANOREXIA; CANCER PROGNOSIS; CANCER SURGERY; CLINICAL FEATURE; DIARRHEA; DIGESTIVE TRACT ENDOSCOPY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; DYSGEUSIA; ENDOSCOPIC ECHOGRAPHY; FATIGUE; FOLLOW UP; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL STROMAL TUMOR; GOLD STANDARD; HAND FOOT SYNDROME; HEADACHE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LOCAL EXCISION; LYMPHOCYTOPENIA; META ANALYSIS (TOPIC); MITOSIS INDEX; MOLECULAR PATHOLOGY; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; ONCOGENE C KIT; OVERALL SURVIVAL; PANCREATICODUODENECTOMY; PERIORBITAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SKIN DISCOLORATION; STOMACH ANTRUM RESECTION; SURVIVAL; THROMBOCYTOPENIA; TUMOR LOCALIZATION; TUMOR VOLUME; WEDGE RESECTION;

ANTINEOPLASTIC AGENTS; BENZAMIDES; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84901506440     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12761     Document Type: Review

References (90)

1. Rubin JL, Sanon M, Taylor DC, Coombs J, Bollu V, Sirulnik L,. Epidemiology, survival, and costs of localized gastrointestinal stromal tumors. Int J Gen Med 2011; 4: 121-30.
2. Tran T, Davila JA, El-Serag HB,. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005; 100: 162-8.
3. Nilsson B, Bumming P, Meis-Kindblom JM, et al,. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005; 103: 821-9.
4. Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC,. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer. 2005; 41: 2868-72.
5. Sandvik OM, Soreide K, Kvaloy JT, Gudlaugsson E, Soreide JA,. Epidemiology of gastrointestinal stromal tumours: single-institution experience and clinical presentation over three decades. Cancer Epidemiol 2011; 35: 515-20.
6. Pisters PW, Blanke CD, von Mehren M, et al,. A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices. Ann Oncol 2011; 22: 2523-9.
7. Miettinen M, Sarlomo-Rikala M, Lasota J,. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999; 30: 1213-20.
8. Miettinen M, Monihan JM, Sarlomo-Rikala M, et al,. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol 1999; 23: 1109-18.
9. Levy AD, Remotti HE, Thompson WM, Sobin LH, Miettinen M,. Gastrointestinal stromal tumors: radiologic features with pathologic correlation. Radiographics 2003; 23: 283-304, 456.
10. Lau S, Tam KF, Kam CK, et al,. Imaging of gastrointestinal stromal tumour (GIST). Clin Radiol 2004; 59: 487-98.
11. Miettinen M, Majidi M, Lasota J,. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer. 2002; 38 (Suppl. 5): S39-51.
12. Miettinen M, Sobin LH, Lasota J,. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29: 52-68.
13. Nishida T, Kumano S, Sugiura T, et al,. Multidetector CT of high-risk patients with occult gastrointestinal stromal tumors. AJR Am J Roentgenol 2003; 180: 185-9.
14. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF,. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-8.
15. Jiang ZX, Zhang SJ, Peng WJ, Yu BH,. Rectal gastrointestinal stromal tumors: imaging features with clinical and pathological correlation. World J Gastroenterol 2013; 19: 3108-16.
16. Carney JA,. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 1999; 74: 543-52.
17. Takazawa Y, Sakurai S, Sakuma Y, et al,. Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease). Am J Surg Pathol 2005; 29: 755-63.
18. Andersson J, Sihto H, Meis-Kindblom JM, Joensuu H, Nupponen N, Kindblom LG,. NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol 2005; 29: 1170-6.
19. Rodriguez SA, Faigel DO,. Endoscopic diagnosis of gastrointestinal stromal cell tumors. Curr Opin Gastroenterol 2007; 23: 539-43.
20. Saund MS, Demetri GD, Ashley SW,. Gastrointestinal stromal tumors (GISTs). Curr Opin Gastroenterol 2004; 20: 89-94.
21. Cantor MJ, Davila RE, Faigel DO,. Yield of tissue sampling for subepithelial lesions evaluated by EUS: a comparison between forceps biopsies and endoscopic submucosal resection. Gastrointest Endosc 2006; 64: 29-34.
22. Paulsen SR, Huprich JE, Fletcher JG, et al,. CT enterography as a diagnostic tool in evaluating small bowel disorders: review of clinical experience with over 700 cases. Radiographics. 2006; 26: 641-57.
23. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 (Suppl. 7): vii49-55.
24. Jenssen C, Alvarez-Sanchez MV, Napoleon B, Faiss S,. Diagnostic endoscopic ultrasonography: assessment of safety and prevention of complications. World J Gastroenterol 2012; 18: 4659-76.
25. Sepe PS, Moparty B, Pitman MB, Saltzman JR, Brugge WR,. EUS-guided FNA for the diagnosis of GI stromal cell tumors: sensitivity and cytologic yield. Gastrointest Endosc 2009; 70: 254-61.
26. Vander Noot MR 3rd, Eloubeidi MA, Chen VK, et al,. Diagnosis of gastrointestinal tract lesions by endoscopic ultrasound-guided fine-needle aspiration biopsy. Cancer 2004; 102: 157-63.
27. Chen VK, Eloubeidi MA,. Endoscopic ultrasound-guided fine-needle aspiration of intramural and extraintestinal mass lesions: diagnostic accuracy, complication assessment, and impact on management. Endoscopy 2005; 37: 984-9.
28. Mazur MT, Clark HB,. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983; 7: 507-19.
29. Newman PL, Wadden C, Fletcher CD,. Gastrointestinal stromal tumours: correlation of immunophenotype with clinicopathological features. J Pathol 1991; 164: 107-17.
30. Romagnoli S, Graziani D, Bramerio M, et al,. Immunohistochemical profile and c-kit mutations in gastrointestinal stromal tumors. Pathol Res Pract 2005; 201: 71-81.
31. Fletcher CD, Berman JJ, Corless C, et al,. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459-65.
32. Hirota S, Isozaki K, Moriyama Y, et al,. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-80.
33. Joensuu H,. Gastrointestinal stromal tumor (GIST). Ann Oncol 2006; 17 (Suppl. 10): x280-6.
34. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M,. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11: 728-34.
35. Russell ES,. Hereditary anemias of the mouse: a review for geneticists. Adv Genet 1979; 20: 357-459.
36. Kitamura Y, Go S,. Decreased production of mast cells in S1/S1d anemic mice. Blood 1979; 53: 492-7.
37. Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A,. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995; 373: 347-9.
38. Linnekin D,. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol 1999; 31: 1053-74.
39. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA,. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002; 33: 484-95.
40. Akin C, Metcalfe DD,. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 2004; 114: 13-9.
41. Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH, O'Leary TJ,. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998; 78: 1633-6.
42. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M,. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154: 53-60.
43. Taniguchi M, Nishida T, Hirota S, et al,. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59: 4297-300.
44. Corless CL, Fletcher JA, Heinrich MC,. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22: 3813-25.
45. Corless CL, Schroeder A, Griffith D, et al,. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23: 5357-64.
46. Feakins RM,. The expression of p53 and bcl-2 in gastrointestinal stromal tumours is associated with anatomical site, and p53 expression is associated with grade and clinical outcome. Histopathology 2005; 46: 270-9.
47. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ,. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23: 82-7.
48. El-Rifai W, Sarlomo-Rikala M, Andersson LC, Knuutila S, Miettinen M,. DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res 2000; 60: 3899-903.
49. Sheehan KM, Sabah M, Cummins RJ, et al,. Cyclooxygenase-2 expression in stromal tumors of the gastrointestinal tract. Hum Pathol 2003; 34: 1242-6.
50. Sevinc A, Camci C, Sari I, et al,. Cyclooxygenase-2 expression in gastrointestinal stromal tumours. Asian Pac J Cancer Prev 2010; 11: 849-53.
51. Jiang J, Jin MS, Suo J, Wang YP, He L, Cao XY,. Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors. World J Gastroenterol 2012; 18: 2569-75.
52. Medeiros F, Corless CL, Duensing A, et al,. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004; 28: 889-94.
53. Liegl B, Hornick JL, Corless CL, Fletcher CD,. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol 2009; 33: 437-46.
54. Miettinen M, Wang ZF, Lasota J,. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol 2009; 33: 1401-8.
55. Yang YD, Cho H, Koo JY, et al,. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature 2008; 455: 1210-5.
56. Caputo A, Caci E, Ferrera L, et al,. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science 2008; 322: 590-4.
57. van de Rijn M, Hendrickson MR, Rouse RV,. CD34 expression by gastrointestinal tract stromal tumors. Hum Pathol 1994; 25: 766-71.
58. Miettinen M, Virolainen M,. Maarit Sarlomo R. Gastrointestinal stromal tumors-value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 1995; 19: 207-16.
59. Blay JY, Bonvalot S, Casali P, et al,. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16: 566-78.
60. Nishida T, Hirota S, Taniguchi M, et al,. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998; 19: 323-4.
61. Crosby JA, Catton CN, Davis A, et al,. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001; 8: 50-9.
62. Dematteo RP, Gold JS, Saran L, et al,. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008; 112: 608-15.
63. Yan H, Marchettini P, Acherman YI, Gething SA, Brun E, Sugarbaker PH,. Prognostic assessment of gastrointestinal stromal tumor. Am J Clin Oncol 2003; 26: 221-8.
64. Hassan I, You YN, Shyyan R, et al,. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol 2008; 15: 52-9.
65. Burkill GJ, Badran M, Al-Muderis O, et al,. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 2003; 226: 527-32.
66. Baker ME, Pelley R,. Hepatic metastases: basic principles and implications for radiologists. Radiology 1995; 197: 329-37.
67. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G,. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002; 33: 466-77.
68. Katrin S, Alexandra F, Michael S, et al,. Surgical treatment of GIST-An institutional experience of a high-volume center. Int J Surg 2013; 11: 801-6.
69. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY,. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl. 4): 64-7.
70. Wu PC, Langerman A, Ryan CW, Hart J, Swiger S, Posner MC,. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery. 2003; 134: 656-65.
71. Roberts PJ, Eisenberg B,. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 2002; 38 (Suppl. 5): S37-8.
72. Rossi CR, Mocellin S, Mencarelli R, et al,. Gastrointestinal stromal tumors: from a surgical to a molecular approach. Int J Cancer 2003; 107: 171-6.
73. Ray-Coquard I, Blay J-Y,. Diagnosis and Management of Gastrointestinal Stromal Tumours. Business Briefing: European Pharmacotherapy, 2005; 2-7.
74. Demetri GD, von Mehren M, Antonescu CR, et al,. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010; 8 (Suppl. 2): S1-41.
75. Levitzki A,. Tyrosine kinases as targets for cancer therapy. Eur J Cancer 2002; 38 (Suppl. 5): S11-8.
76. Manley P, Cowan-Jacob S, Buchdunger E, et al,. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer 2002; 38: S19-27.
77. Tuveson DA, Willis NA, Jacks T, et al,. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001; 20: 5054-8.
78. Druker BJ, Tamura S, Buchdunger E, et al,. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-6.
79. Druker BJ, Talpaz M, Resta DJ, et al,. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7.
80. Druker BJ, Sawyers CL, Kantarjian H, et al,. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-42.
81. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ,. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925-32.
82. Demetri GD, von Mehren M, Blanke CD, et al,. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.
83. Dematteo RP, Ballman KV, Antonescu CR, et al,. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-104.
84. Blanke CD, Rankin C, Demetri GD, et al,. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626-32.
85. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010; 28: 1247-53.
86. Vadakara J, von Mehren M,. Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies. Hematol Oncol Clin North Am 2013; 27: 905-20.
87. Bucher P, Villiger P, Egger JF, Buhler LH, Morel P,. Management of gastrointestinal stromal tumors: from diagnosis to treatment. Swiss Med Wkly 2004; 134: 145-53.
88. Demetri GD, van Oosterom AT, Garrett CR, et al,. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-38.
89. Demetri GD, Reichardt P, Kang YK, et al,. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 295-302.
90. Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T,. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 2003; 6: 39-48.